Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology
Healthcare
$0.61 -1.46%
-$0.03 today
- Market cap
- $109.26M
- Beta
- 0.74
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.37
52W Low $1.61High $6.88
Volume 2.90M
Average 7.64M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$72.84M
FY 2025 · Annual
Net Income
-$66.49M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 850K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.47M |
| Gross Profit | 0 | 0 | 0 | 850K | (1.47M) |
| Gross Margin | — | — | — | 100.0% | — |
| Research & Development | 20.34M | 30M | 38.12M | 42.34M | 55.97M |
| Selling, General & Admin | 10.93M | 11.66M | 12.24M | 15.13M | 16.87M |
| Operating Expenses | 81.88M | 41.66M | 50.36M | 57.48M | 71.37M |
| Depreciation & Amortization | 1.62M | 1.9M | 1.89M | 1.75M | 1.47M |
| EBITDA | (80.19M) | (34.96M) | (40.6M) | (47.62M) | (65.02M) |
| EBITDA Margin | — | — | — | -5602.6% | — |
| Operating Income | (81.88M) | (41.66M) | (50.36M) | (56.63M) | (72.84M) |
| Operating Margin | — | — | — | -6661.8% | — |
| Interest Income | 29K | 2.36M | 7.9M | 7.3M | 6.35M |
| Interest Expense | 370K | 2.36M | 0 | 0 | 0 |
| Other Income / Expenses | (299K) | 2.43M | 7.87M | 7.25M | 6.35M |
| Income Before Tax | (82.18M) | (39.23M) | (42.49M) | (49.38M) | (66.49M) |
| Pre-Tax Margin | — | — | — | -5808.8% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (82.18M) | (39.23M) | (42.49M) | (49.38M) | (66.49M) |
| Net Margin | — | — | — | -5808.8% | — |
| EPS (Basic) | (1.31) | (0.35) | (0.33) | (0.36) | (0.42) |
| EPS (Diluted) | (1.31) | (0.35) | (0.33) | (0.36) | (0.42) |
| 62.87M | 105.19M | 127.03M | 137.11M | 157.7M | |
| 62.87M | 105.19M | 127.03M | 137.11M | 157.7M |
CMPX Earnings Waterfall · TTM
NASDAQ:CMPX · Revenue to Net Income
Key Ratios
EPS$-0.43
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-10.6
P/S Ratio0.0
Analysis
$0 of revenue converted into -$68.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-0.43, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 25, 2026 |
How much revenue does CMPX generate?
Compass Therapeutics, Inc. (CMPX) reported $0.00 of revenue in fiscal 2025.
Is CMPX profitable?
Compass Therapeutics, Inc. (CMPX) reported -$66.49M of net income.
Continue the stock analysis
Jump to another research area for this company.